AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33958779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 430
Study 32499069 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-mm intramedullary headless compression screw
Number of subjects: 30
Study 32499069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-mm T-plate
Number of subjects: 30
Study 32499069 — intervention group
Group type: COMPARATOR
Intervention: 2 oblique 1.0-mm Kirschner wires
Number of subjects: 30
Study 35440464 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab with chemotherapy (cisplatin plus paclitaxel)
Number of subjects: 659
Study 35440464 — intervention group
Group type: COMPARATOR
Intervention: placebo with chemotherapy (cisplatin plus paclitaxel)
Number of subjects: 659
Study 35440464 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab with chemotherapy (cisplatin plus 5‐fluorouracil)
Number of subjects: 659
Study 35440464 — intervention group
Group type: COMPARATOR
Intervention: placebo with chemotherapy (cisplatin plus 5‐fluorouracil)
Number of subjects: 659
Study 32492135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (highest compared with lowest quintile)
Number of subjects: 101
Study 32492135 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (highest compared with lowest quintile)
Number of subjects: 101
Study 32492135 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit consumption (highest compared with lowest quintile)
Number of subjects: 101
Study 32492135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy products (highest compared with lowest quintile)
Number of subjects: 101
Study 32492135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-vegetarian dietary pattern
Number of subjects: 101
Study 36450482 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise with HTS (Hybrid Training System)
Number of subjects: 32
Study 36450482 — intervention group
Group type: COMPARATOR
Intervention: Control group (Walking exercise without HTS)
Number of subjects: 32
Study 36450482 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise with HTS
Number of subjects: 32
Study 33063334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Effects (FE) estimators (gain score and deviation score estimators)
Number of subjects: 0
Study 33063334 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Effects (RE) estimators (quasi-deviation score estimators)
Number of subjects: 0
Study 33063334 — intervention group
Group type: COMPARATOR
Intervention: Standard regression or matching estimators
Number of subjects: 0
Study 33376173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines management
Number of subjects: 386
Study 33376173 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 386
Study 32996172 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) with scaling and root planing (SRP)
Number of subjects: 51
Study 32996172 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy alone (control)
Number of subjects: 51
Study 34185091 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) glasses during painful dressing procedures
Number of subjects: 79
Study 34185091 — intervention group
Group type: EXPERIMENTAL
Intervention: Wong-Baker Faces Pain Scale
Number of subjects: 79
Study 34185091 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Fear Scale
Number of subjects: 79
Study 34555333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 21 days for 16 cycles or 1 year)
Number of subjects: 1005
Study 34555333 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (observation and regular scans for disease recurrence)
Number of subjects: 1005
Study 34555333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1005
Study 32400354 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiyear mass drug administration (MDA) with praziquantel, provided biannually and/or supplemented by additional interventions.
Number of subjects: 0
Study 32400354 — intervention group
Group type: EXPERIMENTAL
Intervention: T5 strategy (test–treat–track–test–treat) implemented in Egypt, Kenya, and Tanzania.
Number of subjects: 0
Study 33607066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker system with standardized language for follow-up recommendations
Number of subjects: 1036
Study 33607066 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention (no tracker system)
Number of subjects: 1036
Study 36307187 — intervention group
Group type: EXPERIMENTAL
Intervention: NHF 6 L/min, FiO2 1.0
Number of subjects: 43
Study 36307187 — intervention group
Group type: COMPARATOR
Intervention: NHF 0 L/min (control)
Number of subjects: 43
Study 34618744 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured neonatal physical therapy program (SNP), 90 minutes/day, 6 days/week until discharge
Number of subjects: 60
Study 34618744 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 32997907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 572
Study 32997907 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 572
Study 33397772 — intervention group
Group type: EXPERIMENTAL
Intervention: SB623 (2.5 × 10^6, 5.0 × 10^6, 10 × 10^6 cells)
Number of subjects: 63
Study 33397772 — intervention group
Group type: COMPARATOR
Intervention: Control (sham surgery)
Number of subjects: 63
Study 33397772 — intervention group
Group type: EXPERIMENTAL
Intervention: SB623
Number of subjects: 63
Study 33397772 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 35458107 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low caloric diet (VLCD) for 6 weeks followed by a 2-week weight-maintenance period
Number of subjects: 54
Study 33471439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 40% of maximum inspiratory pressure (MIP) for 8 weeks
Number of subjects: 0
Study 33471439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33471439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 0
Study 35131178 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual training for INR self-testing
Number of subjects: 33683
Study 35131178 — intervention group
Group type: COMPARATOR
Intervention: In-Person training for INR self-testing
Number of subjects: 33683
Study 33267922 — intervention group
Group type: EXPERIMENTAL
Intervention: Grocery Purchase Quality Index (GPQI) scores (mean 54.8%)
Number of subjects: 209
Study 33267922 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating Index (HEI) scores (baseline: 73.2%, 3 months: 72.4%)
Number of subjects: 209
Study 33297831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar drink (two tablespoons vinegar in a cup of water; 3.6 g acetic acid)
Number of subjects: 0
Study 33297831 — intervention group
Group type: COMPARATOR
Intervention: Commercial vinegar pill (control, 0.045 g acetic acid)
Number of subjects: 0
Study 33027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 699
Study 33027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 699
Study 35708015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas stove and fuel during pregnancy
Number of subjects: 3195
Study 35708015 — intervention group
Group type: COMPARATOR
Intervention: Solid fuels (control)
Number of subjects: 3195
Study 35708015 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposure to household air pollution
Number of subjects: 3195
Study 34090183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 102
Study 34090183 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia
Number of subjects: 102
Study 32424576 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 35
Study 32424576 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in urologic therapy
Number of subjects: 35
Study 33504249 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMM intervention (n = 31)
Number of subjects: 56
Study 33504249 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 25)
Number of subjects: 56
Study 32870434 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis using Shepard's cannula and lactated Ringer's solution
Number of subjects: 30
Study 32870434 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticosteroid (GCS) injection using 1 ml/40 mg methylprednisolone acetate
Number of subjects: 30
Study 35594551 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2)
Number of subjects: 46
Study 35594551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33901450 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening Suturing (OSu)
Number of subjects: 84
Study 33901450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screw Anchor (MsA)
Number of subjects: 84
Study 33901450 — intervention group
Group type: COMPARATOR
Intervention: No treatment (before disc repositioning)
Number of subjects: 84
Study 32143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative factors associated with loss-to-follow-up (LTFU)
Number of subjects: 49
Study 34989159 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day) in addition to usual care
Number of subjects: 133
Study 34989159 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 133
Study 34782018 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking fOR Health (WORtH) multi‐component behaviour change intervention (education, goal-setting, self-monitoring)
Number of subjects: 60
Study 34782018 — intervention group
Group type: COMPARATOR
Intervention: One-off education session
Number of subjects: 60
Study 34782018 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking fOR Health (WORtH) multi‐component behaviour change intervention
Number of subjects: 60
Study 33380481 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey data from the Health and Housing in Transition study and the At Home/Chez Soi study
Number of subjects: 0
Study 33380481 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 0
Study 33380481 — intervention group
Group type: EXPERIMENTAL
Intervention: Count models
Number of subjects: 0
Study 34048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of eBEACOPP
Number of subjects: 1945
Study 34048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of rituximab plus eBEACOPP
Number of subjects: 1945
Study 34048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of eBEACOPP
Number of subjects: 1945
Study 34048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight or six cycles of eBEACOPP
Number of subjects: 1945
Study 34048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of eBEACOPP
Number of subjects: 1945
Study 32066504 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulphate (PK‐Merz®; twice 100 mg orally daily)
Number of subjects: 36
Study 32066504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32066504 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 36
Study 35505326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day) alone
Number of subjects: 545
Study 35505326 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) alone
Number of subjects: 545
Study 35505326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day) combined with Calcium (600 mg)
Number of subjects: 545
Study 35505326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 33272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release pregabalin (GLA5PR GLARS-NF1 tablets)
Number of subjects: 352
Study 33272643 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release pregabalin capsule
Number of subjects: 352
Study 35659231 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive transfluthrin emanator
Number of subjects: 0
Study 35659231 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 36245417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)
Number of subjects: 158
Study 36245417 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 158
Study 33691667 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) intervention
Number of subjects: 434
Study 33691667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 434
Study 32778434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group choir singing
Number of subjects: 31
Study 36658521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby box group
Number of subjects: 100
Study 36658521 — intervention group
Group type: COMPARATOR
Intervention: Diaper bag group
Number of subjects: 100
Study 33884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 121
Study 33884414 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed weight loss
Number of subjects: 121
Study 33884414 — intervention group
Group type: COMPARATOR
Intervention: Coach‐directed weight loss
Number of subjects: 121
Study 32073415 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop sign position (shoulder abducted and externally rotated to 90°, elbow flexed to 90°)
Number of subjects: 62
Study 32073415 — intervention group
Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 62
Study 34364814 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab followed after progression by regorafenib
Number of subjects: 214
Study 34364814 — intervention group
Group type: COMPARATOR
Intervention: Reverse sequence (regorafenib followed by panitumumab)
Number of subjects: 214
Study 32500717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (two tablets of 333 mg/d, three times a day)
Number of subjects: 20
Study 32500717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets, three times a day)
Number of subjects: 20
Study 35267992 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet
Number of subjects: 90
Study 35267992 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 90
Study 35005013 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 124
Study 35005013 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 124
Study 35005013 — intervention group
Group type: COMPARATOR
Intervention: morphine
Number of subjects: 124
Study 36318924 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 0
Study 36318924 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approaches (including LRH)
Number of subjects: 0
Study 36318924 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 0
Study 33368929 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving and Story-bridge based mental health literacy programme
Number of subjects: 25
Study 36291340 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 12
Study 35545297 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing for Lung Health (SLH)
Number of subjects: 108
Study 36036644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with physical therapy
Number of subjects: 82
Study 36036644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with physical therapy
Number of subjects: 82
Study 36036644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tDCS combined with physical therapy
Number of subjects: 82
Study 36036644 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with physical therapy
Number of subjects: 82
Study 34373303 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Insights principles for public programme communication
Number of subjects: 2003
Study 34373303 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 2003
Study 34154492 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPR (web-based support program including booklet and online videos)
Number of subjects: 130
Study 34154492 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (no support)
Number of subjects: 130
Study 34096381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and counseling intervention (details on dosage and duration not specified)
Number of subjects: 438
Study 35428720 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 175
Study 34606332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 2 g (therapeutic)
Number of subjects: 72
Study 34606332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 4 g (supratherapeutic)
Number of subjects: 72
Study 34606332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34606332 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive comparator)
Number of subjects: 72
Study 36264894 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ programme (F11+)
Number of subjects: 90
Study 36264894 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified warm-up programme (M11+)
Number of subjects: 90
Study 36264894 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine warm-ups)
Number of subjects: 90
Study 36264894 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ programme (F11+) and Modified warm-up programme (M11+)
Number of subjects: 90
Study 32648790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 28
Study 32648790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 35007899 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil inhalation (100% peppermint essential oil, 1 hour duration)
Number of subjects: 64
Study 33846086 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphir RX
Number of subjects: 95
Study 33846086 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua for Astigmatism
Number of subjects: 95
Study 33846086 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Toric
Number of subjects: 95
Study 33846086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Vita for Astigmatism
Number of subjects: 95
Study 36215267 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR (used continuously or cyclically)
Number of subjects: 47
Study 36215267 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Number of subjects: 47
Study 36215267 — intervention group
Group type: COMPARATOR
Intervention: Placebo IVR
Number of subjects: 47
Study 34763080 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) using BrainHQ
Number of subjects: 256
Study 34763080 — intervention group
Group type: COMPARATOR
Intervention: Computerized crossword puzzles (active control)
Number of subjects: 256
Study 34763080 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 34052943 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation (CS) with propofol and sufentanil (0.1 mg/kg)
Number of subjects: 115
Study 34052943 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation (DS) with propofol and sufentanil (0.05 mg/kg)
Number of subjects: 115
Study 34052943 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation (CS)
Number of subjects: 115
Study 34052943 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation (DS)
Number of subjects: 115
Study 32026447 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter lesions (WML) grade 1-4 at dCT
Number of subjects: 635
Study 32026447 — intervention group
Group type: COMPARATOR
Intervention: Primary HE endpoint (> 33% or > 6 mL ICH volume increase)
Number of subjects: 635
Study 32026447 — intervention group
Group type: COMPARATOR
Intervention: Secondary HE outcomes (absolute ICH expansion, > 10.4 mL total clot volume increase)
Number of subjects: 635
Study 35934188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-Bearing TKA
Number of subjects: 98
Study 35934188 — intervention group
Group type: COMPARATOR
Intervention: Fixed-Bearing TKA
Number of subjects: 98
Study 33422047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text message
Number of subjects: 286
Study 33422047 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 286
Study 33422047 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 286
Study 33422047 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based Motivational Interviewing (MI)
Number of subjects: 286
Study 32966475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed meal (FM) supplemented biscuits
Number of subjects: 53
Study 32966475 — intervention group
Group type: COMPARATOR
Intervention: Control biscuits
Number of subjects: 53
Study 616391466 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 616391466 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion (ATD)
Number of subjects: 0
Study 616391466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 616391466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biperiden and ATD
Number of subjects: 0
Study 35094138 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated machine learning-based prognostic algorithm (previous exposure in a pragmatic randomized trial)
Number of subjects: 29
Study 35094138 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated machine learning-based prognostic algorithm
Number of subjects: 29
Study 32831908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 + a calcinated magnesium placebo (n = 16)
Number of subjects: 40
Study 32831908 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of Vitamin K2 + a calcinated magnesium placebo (n = 12)
Number of subjects: 40
Study 32831908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 + 100 μg vitamin K2 (n = 12)
Number of subjects: 40